Strongbridge Biopharma plc
SBBP · NASDAQ
6/30/2021 | 3/31/2021 | 12/31/2020 | 9/30/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.34 | 0.28 | -0.01 | 0.11 |
| FCF Yield | -4.89% | -7.21% | -3.67% | -4.90% |
| EV / EBITDA | -13.92 | -13.31 | -6.53 | -32.14 |
| Quality | ||||
| ROIC | -17.52% | -11.64% | -10.37% | -9.75% |
| Gross Margin | 95.35% | 95.10% | 94.63% | 94.94% |
| Cash Conversion Ratio | 0.74 | 1.13 | 0.42 | 1.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.62% | 20.59% | 19.46% | 19.44% |
| Free Cash Flow Growth | 26.68% | -168.06% | 13.33% | 52.46% |
| Safety | ||||
| Net Debt / EBITDA | 4.09 | 5.75 | 6.94 | 54.50 |
| Interest Coverage | -16.13 | -12.88 | -18.57 | -18.33 |
| Efficiency | ||||
| Inventory Turnover | 0.42 | 0.41 | 0.40 | 0.37 |
| Cash Conversion Cycle | 121.90 | -1,005.43 | -46.73 | -71.84 |